Robotic-Assisted Versus Manual Electrode Array Insertion

NCT ID: NCT06951594

Last Updated: 2025-07-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-30

Study Completion Date

2028-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Robotics-assisted electrode insertion overcomes many surgeon-related kinetic limitations such as insertion speed, tremor, drift, and lack of accurate force control. In human cadaveric cochleae, robotics-assisted electrode insertion causes less intracochlear trauma compared to manual insertion. Whether this technical advance results in functional benefits in CI patients remains unknown. To address this critical knowledge gap, the investigators will compare cochlear trauma assessed using CT scans, cochlear and AN function assessed using ECochG and/or the eCAP, and clinical outcomes quantified by postoperative residual acoustic hearing and speech perception scores between participants randomized to either manual or robotics-assisted electrode array insertion.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Electrode insertion force is a critical determinant of the degree/amount of intracochlear trauma caused by CI surgery. It is affected by the speed of electrode array insertion, with higher insertion speeds leading to greater insertion forces. In addition, rapid electrode array insertions with higher forces are associated with translocation of electrode arrays from the scala tympani into the scala media or vestibuli which leads to lower performance and higher rates of loss of residual hearing. Furthermore, variability in insertion force during electrode insertion can cause dramatic increases in intracochlear fluid pressure which appears to be traumatic. The recent FDA-approved iotaSOFT™ insertion system is designed to address these issues by controlling the speed of implant insertion (0.1-1.0 mm/sec) with reduced insertion force and variability. Use of the iotaSOFT™ insertion system significantly reduces the maximum insertion force, variation in insertion force and intracochlear pressure changes over time, which leads to decreased intracochlear trauma compared with manual insertion in cadavers. In addition, this robotics-assisted insertion system can be used with ECochG monitoring systems, which enables response dynamics that can dramatically reduce electrode array stopping distances (1-2 µm of further electrode array advancement) compared to the kinetics of human manual insertion (\~1 mm) once a change in intraoperative ECochG response is detected. Theoretically, robotics-assisted electrode array insertion should result in better preserved structural and functional integrity of the peripheral auditory system due to reduced intracochlear trauma. However, this theoretical possibility has not been tested in human CI users.

To address this knowledge gap, the investigators propose to determine the functional benefits of using robotics-assisted electrode insertion in reducing intracochlear trauma. This will be achieved by comparing trauma to the cochlea from electrode insertion based on postoperative CT scans, electrode impedance, the functional status of the cochlea and the AN, as well as preservation of acoustic hearing in participants randomized to have the electrode array inserted manually or with the iotaSOFT™ insertion system. The investigators hypothesize that robotics-assisted electrode insertion will better preserve peripheral structural and functional integrity by reducing intraoperative trauma. The investigators expect that participants with robotics-assisted electrode insertions will show smaller trauma scores based on CT scans, lower electrode impedance, better functional statuses of the AN, higher ENI indices, less hearing loss, and improved speech perception scores than participants with manual electrode insertions.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cochlear Implantation Robotics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Robot

The iotaSOFT™ Insertion System is an FDA approved cochlear implant (CI) electrode array insertion tool. It will be used to assist the surgeon with the cochlear implant insertion.

Group Type EXPERIMENTAL

Robotic

Intervention Type DEVICE

The iotaSOFT™ Insertion System is an FDA approved cochlear implant (CI) electrode array insertion tool. It provides surgeons with consistent insertion speed and force. The system consists of a drive unit connected to a touch screen control console and foot pedal interface. The surgeon secures the base to the skull with two pre-loaded self-drilling bone screws. The drive unit is placed into the base and the adjustable drive head is coupled to a CI electrode. Before insertion begins, the surgeon selects the desired speed of insertion. the surgeon controls the electrode insertion forward and reverse motion via foot pedal while guiding the electrode array into the cochlea with standard CI instrumentation. Upon the completion of electrode array insertion, the drive head and unit are uncoupled from the electrode lead and removed from the patient for disposal.

Manual

Manual cochlear implant surgical procedure without robotic assistance.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Robotic

The iotaSOFT™ Insertion System is an FDA approved cochlear implant (CI) electrode array insertion tool. It provides surgeons with consistent insertion speed and force. The system consists of a drive unit connected to a touch screen control console and foot pedal interface. The surgeon secures the base to the skull with two pre-loaded self-drilling bone screws. The drive unit is placed into the base and the adjustable drive head is coupled to a CI electrode. Before insertion begins, the surgeon selects the desired speed of insertion. the surgeon controls the electrode insertion forward and reverse motion via foot pedal while guiding the electrode array into the cochlea with standard CI instrumentation. Upon the completion of electrode array insertion, the drive head and unit are uncoupled from the electrode lead and removed from the patient for disposal.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Candidate for a cochlear implant according to CMS guidelines
* Willingness to comply with all study requirements
* Patent cochlea and normal cochlear anatomy, as confirmed by preoperative imaging
* English speaking

Exclusion Criteria

* Medical or psychological conditions that contraindicate undergoing surgery
* Ossification or any other cochlear anomaly that might prevent complete insertion of the electrode array.
* Unrealistic expectations on the part of the candidate and/or candidate's family, regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure(s) and prosthetic devices.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Iowa

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Bruce J Gantz

Chair Emeritus, Department of Otolaryngology--Head and Neck Surgery

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bruce Gantz, MD

Role: PRINCIPAL_INVESTIGATOR

University of Iowa

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Iowa Healthcare

Iowa City, Iowa, United States

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Rachel Scheperle, PhD

Role: CONTACT

319-384-9031

Camille Dunn, PhD

Role: CONTACT

319-353-8776

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Rachel Scheperle, PhD

Role: primary

319-384-9031

Camille Dunn, PhD

Role: backup

319-353-8776

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

202210440

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Auditory Midbrain Implant Study
NCT02984202 COMPLETED NA